CA2340929A1 - Technique propre a accentuer et a confiner l'expression de genes - Google Patents

Technique propre a accentuer et a confiner l'expression de genes Download PDF

Info

Publication number
CA2340929A1
CA2340929A1 CA002340929A CA2340929A CA2340929A1 CA 2340929 A1 CA2340929 A1 CA 2340929A1 CA 002340929 A CA002340929 A CA 002340929A CA 2340929 A CA2340929 A CA 2340929A CA 2340929 A1 CA2340929 A1 CA 2340929A1
Authority
CA
Canada
Prior art keywords
promoter
tet
cassette
dbd
gal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002340929A
Other languages
English (en)
Inventor
Yuen Kai Fung
Charles Gomer
Anne T'ang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2340929A1 publication Critical patent/CA2340929A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une nouvelle approche de thérapie génique appliquée à des zones restreintes telles que des tumeurs. La démarche décrite ici consiste à: (a) placer un gène d'intérêt dans un vecteur plasmidique entraîné par un promoteur inductible par la chaleur ou par la lumière; (b) modifier ce vecteur par inclusion d'une protéine de fusion sensible à la tétracycline et agissant comme activateur de transcription, ce qui permet de réguler l'expression du gène en jouant sur la concentration du médicament et; (c) modifier ce vecteur en incluant des séquences d'ADN qui réduisent ou suppriment l'expression de gènes dans des cellules normales de voisinage. L'invention concerne aussi un ensemble de vecteurs à expression tant continue que régulable. Sont également décrits de nouveaux vecteurs destinésà la thérapie génique des cancers du sein, des ovaires et de la prostate, localisés ou métastatiques.
CA002340929A 1998-08-18 1999-08-18 Technique propre a accentuer et a confiner l'expression de genes Abandoned CA2340929A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9694798P 1998-08-18 1998-08-18
US60/096,947 1998-08-18
PCT/US1999/019095 WO2000010612A1 (fr) 1998-08-18 1999-08-18 Technique propre a accentuer et a confiner l'expression de genes

Publications (1)

Publication Number Publication Date
CA2340929A1 true CA2340929A1 (fr) 2000-03-02

Family

ID=22259886

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002340929A Abandoned CA2340929A1 (fr) 1998-08-18 1999-08-18 Technique propre a accentuer et a confiner l'expression de genes

Country Status (11)

Country Link
EP (1) EP1109582A4 (fr)
JP (1) JP2002523032A (fr)
KR (1) KR20020013463A (fr)
CN (1) CN1321093A (fr)
AU (1) AU763183B2 (fr)
CA (1) CA2340929A1 (fr)
IL (1) IL141473A0 (fr)
NZ (1) NZ509966A (fr)
RU (1) RU2226108C2 (fr)
WO (1) WO2000010612A1 (fr)
ZA (1) ZA200101207B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105458A1 (en) * 2002-08-09 2006-05-18 Sidney Cambridge Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression
KR20030019282A (ko) * 2002-11-27 2003-03-06 김상태 βAPP의 C말단 pCT105 원격제어에 의한 치매발병 유도 세포주 개발
AU2006227634B2 (en) * 2005-03-16 2010-07-08 Metabolix, Inc. Chemically inducible expression of biosynthetic pathways
CA2780671A1 (fr) * 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Systemes d'expression regulee
CN101892256B (zh) * 2010-01-27 2012-05-09 中国农业科学院北京畜牧兽医研究所 一种培育猪生长激素表达量增强的转基因动物的方法
US9717781B2 (en) 2011-08-08 2017-08-01 Alexander Shneider Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
CN102786599B (zh) * 2012-08-01 2014-01-15 中国农业科学院作物科学研究所 水稻转录因子Os05g39950基因的应用
SG11201605316VA (en) 2013-12-29 2016-07-28 Curelab Oncology Inc Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
CN105925609B (zh) * 2016-07-14 2019-01-08 中国医学科学院输血研究所 带有标记基因的Tet-on诱导过表达的重组载体及构建方法
CN110016464A (zh) * 2018-01-08 2019-07-16 张晋宇 用于筛选抗肿瘤物质的系统及方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4994596A (en) * 1995-03-01 1996-09-18 Cornell Research Foundation Inc. Interdependent adenoviral vectors and methods of using same
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems
JP2001501458A (ja) * 1996-08-15 2001-02-06 アメリカ合衆国 ヒートショックタンパク質プロモーターと局部加熱との組合せを利用した遺伝子発現の場所的及び時期的制御

Also Published As

Publication number Publication date
KR20020013463A (ko) 2002-02-20
NZ509966A (en) 2003-07-25
EP1109582A1 (fr) 2001-06-27
IL141473A0 (en) 2002-03-10
AU5684599A (en) 2000-03-14
WO2000010612A1 (fr) 2000-03-02
AU763183B2 (en) 2003-07-17
EP1109582A4 (fr) 2004-11-03
RU2226108C2 (ru) 2004-03-27
JP2002523032A (ja) 2002-07-30
ZA200101207B (en) 2007-01-31
CN1321093A (zh) 2001-11-07

Similar Documents

Publication Publication Date Title
US20020065243A1 (en) Methods to enhance and confine expression of genes
Dong et al. Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors
AU763714B2 (en) Gene therapy vectors and their use in antitumour therapy
US6242258B1 (en) Methods for the selective regulation of DNA and RNA transcription and translation by photoactivation
AU763183B2 (en) Methods to enhance and confine expression of genes
Marples et al. Molecular approaches to chemo-radiotherapy
US9043994B2 (en) Cre-lox based gene knockdown constructs and methods of use thereof
Lee et al. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy
KR20220078650A (ko) 이중 바이러스 및 이중 종양용해 바이러스 및 치료 방법
AU5318299A (en) Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
Scott et al. Radiation and hypoxia inducible gene therapy systems
WO2001030799A1 (fr) Renforcement et confinement de l'expression genique en therapie anticancereuse
Liaudet-Coopman et al. A tetracycline-responsive promoter system reveals the role of a secreted binding protein for FGFs during the early phase of tumor growth
US20060068391A1 (en) Targeting of herpes simplex virus to specific receptors
US7267978B1 (en) Chimeric transcriptional regulatory element compositions and methods for increasing prostate-targeted gene expression
MXPA01001776A (en) Methods to enhance and confine expression of genes
Wang et al. Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation
Culver et al. Gene therapy for brain tumors
KR20160100010A (ko) 테트라사이클린에 의해 유전자 발현이 조절되는 재조합 벡터
Scanlon et al. Gene regulation in cancer gene therapy strategies
Senner et al. In vivo glioma model enabling regulated gene expression
KR102471898B1 (ko) 면역관문 억제제를 발현하는 암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도
WO2006017741A2 (fr) Promoteur iex-1 inductible par rayonnement
Wang et al. A high-efficiency translational control element with potential for cancer gene therapy
US20020182733A1 (en) Vector and methods of use for selective expression of genes in sites of angiogenesis in vivo

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued